Full-Time

Quality Control Testing Scheduler

Posted on 12/20/2024

Legend Biotech

Legend Biotech

1,001-5,000 employees

Develops and commercializes cell therapies

Biotechnology
Healthcare

Junior, Mid

Bridgewater Township, NJ, USA

Onsite position.

Category
Biology Lab & Research
Biology & Biotech
Requirements
  • Bachelor’s degree in science, Engineering or equivalent technical discipline is required.
  • Minimum of 2-4 year work experience, within a GMP biological and/or pharmaceutical industry is required.
  • Knowledge of cGMP and GDP regulations and FDA/EU guidance related to manufacturing of cell-based products is required.
  • Detailed knowledge of CAR-T QC test methods and related equipment is preferred.
  • Excellent written and oral communication skill are required.
  • Off-hour responses may be required to support business needs.
  • Candidates must be able to accommodate unplanned overtime (including nights and weekends) on little to no prior notice.
  • The candidate must be highly organized and capable of working in a team environment with a positive attitude under some supervision.
  • Comfortable with speaking and interacting with inspectors.
Responsibilities
  • Configure, monitor, and maintain job scheduling systems (e.g Smart QC, BINOC)
  • Design and implement automated testing scheduling workflows to optimize system performance and efficiency alongside with analysts’ tasks and time
  • Monitor test execution, adjust schedule as needed to address tests failures.
  • Maintain detailed documentation of tests schedules, procedures, and any changes made to the schedule
  • Work closely with other analysts, senior analysts, supervisors, and management to ensure that testing schedules align with organizational needs.
  • Generate reports on test performance, including success rates, failures, run, and delay times
  • Participate in change management processes to ensure that all routine testing scheduling changes are properly vetted and documented.
  • Identify opportunities for process improvement in scheduling and workflow automation that allows workload to be evenly distributed amongst all analysts.
  • Ensure Good Documentation Practices and lab readiness are upheld for potential support of regulatory agency audits.
  • Includes the following but not limited to: assist with lab cleanings, logbook review, request of logbooks, filing training records, assist with lab organization

Legend Biotech develops and commercializes cell therapies aimed at treating serious diseases, particularly cancers like hematological malignancies and solid tumors. Their approach is technology agnostic, allowing them to explore various methods to find effective treatments. The company operates in the personalized medicine sector, focusing on discovering, developing, and bringing new therapies to market. They generate revenue through licensing and selling their therapies, including CAR-T therapies, which involve modifying a patient's own cells to combat cancer. Legend Biotech emphasizes transparency with investors, regularly updating them on financial results and business developments.

Company Stage

IPO

Total Funding

$146.4M

Headquarters

Franklin Township, New Jersey

Founded

2014

Growth & Insights
Headcount

6 month growth

15%

1 year growth

40%

2 year growth

102%
Simplify Jobs

Simplify's Take

What believers are saying

  • CARVYKTI® received FDA and European Commission approval for expanded use in multiple myeloma.
  • Legend Biotech is expanding R&D with a new facility in Philadelphia.
  • Collaboration with Multiply Labs aims to automate and improve cell therapy manufacturing.

What critics are saying

  • Increased competition from Amgen's Imdelltra could impact Legend's market share.
  • Expansion into new R&D facilities may strain financial resources.
  • Dependency on external technology through partnerships like MaxCyte could pose risks.

What makes Legend Biotech unique

  • Legend Biotech focuses on personalized cell therapies for hard-to-treat cancers.
  • The company is technology agnostic, exploring multiple platforms for effective treatments.
  • Legend Biotech's CARVYKTI® is the first BCMA-targeted CAR-T therapy approved for second-line treatment.

Help us improve and share your feedback! Did you find this helpful?